No Data
No Data
H.C. Wainwright Maintains Protalix Biotherapeutics(PLX.US) With Buy Rating, Maintains Target Price $15
Protalix BioTherapeutics' CFO Rubin to Leave
NYSE American New 52-Week Highs And Lows
Protalix Biotherapeutics Is Developing Innovative Treatments for Rare Diseases With Its Proprietary ProCellEx Plant Cell Expression System | NYSE-A:PLX
Protalix BioTherapeutics to Present at the IAccess Alpha Virtual Best Ideas Spring Conference 2025
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?